Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting
Stockholm – November 13, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12.
ASH is the world’s largest professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases.
The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
“This long-term follow-up of OCEAN confirms the favorable safety and overall survival outcomes of melflufen + dexametason in patients that have not progressed within 36 months after a stem cell transplantation and supports its use in patients with relapsed, refractory multiple myeloma,” says Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital. “We are happy to have been selected to present our findings at ASH and look forward to the opportunity.”
Find more details about the abstract and presentation below. The abstract including key data has been published and is available through this link.
For more information about ASH Annual Meeting and Exposition, click here.
| Title | Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) |
| Publication Number | 2018 |
| Presenting author | Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital |
| Program | Oral and Poster Abstracts |
| Session | 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I |
Investor Q&A
What is this?
Oncopeptides has had a poster accepted and is invited to present it at the ASH Annual Meeting and Exposition in December.
What is a poster?
In the world of medicine it is a means of academic communication that allows researchers, scholars, and clinicians to present their research findings or clinical case reports in a visual and succinct format. Posters are used at medical conferences as a form of scholarly output alongside oral presentations and published abstracts.
The poster is usually designed to fit a specific size requirement and is displayed in a designated area during the conference. Attendees can view the posters at their leisure, and there are often dedicated sessions when the authors stand by their poster to discuss their work with other conference participants.
The main advantages of a poster presentation are the opportunity for personal interaction and detailed discussion with interested peers, and the chance to receive feedback and potentially form collaborations.
How does the selection process look like?
Typically, more than 5,000 scientific abstracts are submitted each year and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
Will the poster or presentation be available to the public?
The poster will be published on Oncopeptides web site following the congress. An abstract including key results is already available.